Merck & Co. is enjoying a spurt of new drug launches, partly due to its $41 billion November acquisition of New Jersey neighbor Schering-Plough Corp. Some have been on the market in the United States for a while, including blockbuster diabetes medicine Januvia, and are now being launched in other countries.
| Drug Name | Condition/Use | Where It’s Launching |
| Asmanex | Asthma? | Japan |
| Bridion | Reversal of?anesthesia | 30?countries?outside?the?U.S. |
| Elonva | Fertility?treatment | European?Union |
| Januvia | Type?2?diabetes | Japan |
| Remeron | Depression | Japan |
| Saflutan | Glaucoma | European?Union |
| Saphris | Schizophrenia/bipolar?disorder | United?States |
| Simponi | Immune?disorders | 5?countries |
| Tredaptive | Hardening?of?the?arteries | 27?countries?outside?the?U.S. |
